Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Klotho Neurosciences ( (KLTO) ) has shared an update.
On May 28, 2025, Klotho Neurosciences‘ stockholders approved a reverse stock split of the company’s common stock, with an exchange ratio ranging from one-for-2 to one-for-50, as decided by the Board of Directors. This decision, supported by a significant majority of the stockholders, aims to adjust the company’s stock structure, potentially impacting its market positioning and shareholder value.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. operates within the biotechnology industry, focusing on developing innovative treatments for neurological disorders. The company is engaged in research and development to address unmet medical needs in the neuroscience sector.
Average Trading Volume: 10,925,940
Technical Sentiment Signal: Sell
Current Market Cap: $5.91M
For a thorough assessment of KLTO stock, go to TipRanks’ Stock Analysis page.